INCY · Categories · Conferences
INCY - Conference and earnings call announcements
Incyte Corp. (INCY) conference and earnings call announcements - real-time wire coverage filtered to Conferences only.
Recent Conferences for INCY
- Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceIncyte (NASDAQ:INCY) announced today that it will present at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 8:40 a.m. EDT. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte Incyte is redefining what's possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity. To learn more, visit Incyte.com and Invest
- Incyte to Present at Upcoming Investor ConferencesIncyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of May: BofA Securities 2026 Health Care Conference on Wednesday, May 13, 2026 at 1:40 pm (PDT) and RBC 2026 Global Healthcare Conference on Tuesday, May 19, 2026 at 10:30 am (EDT) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte Incyte is redefining what's possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generati
- Incyte to Present at Upcoming Investor ConferencesIncyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of March: TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 10:30 am (EST) Leerink Partners 2026 Global Healthcare Conference on Tuesday, March 10, 2026 at 9:20 am (EDT) and Barclays 28th Annual Global Healthcare Conference on Wednesday, March 11, 2026 at 8:30 am (EDT) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet me
- Incyte to Present at Upcoming Investor ConferenceIncyte (NASDAQ:INCY) announced today that it will present at the 44th Annual J. P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 am (PST). The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquarter
- Incyte to Present at Upcoming Investor ConferencesIncyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of December: Citi's 2025 Global Healthcare Conference on Tuesday, December 2, 2025 at 11:15 am (EST) 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 1:20 pm (EST) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has
- Incyte to Present at Upcoming Investor ConferencesIncyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of November: Guggenheim Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 10:00 am (EST) Jefferies Global Healthcare Conference (London) on Tuesday, November 18, 2025 at 11:00 am (GMT) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therap
- Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal AdenocarcinomaData presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancer Planned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026 Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patients Incyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (NASDAQ:INCY) announced the first clinica
- Data from Incyte's TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025Incyte (NASDAQ:INCY) today announced that results from Phase 1 proof-of-concept studies of INCA33890, a promising TGFβR2×PD-1-directed bispecific antibody, and INCB161734, a novel, selective and orally bioavailable KRAS G12D inhibitor, will be highlighted as oral presentations at the upcoming European Society of Medical Oncology (ESMO) Congress 2025 in Berlin. "We are encouraged by the positive findings being presented with our TGFβR2×PD-1 and KRAS G12D inhibitor programs, which validate our rationale for advancing the development of these novel investigational compounds," said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. "There remains a significant nee
- Incyte to Present at Upcoming Investor ConferencesIncyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of September: Cantor Global Healthcare Conference on Wednesday, September 3, 2025 at 8:00 am (EDT) Well Fargo Healthcare Conference on Thursday, September 4, 2025 at 8:45 am (EDT) Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 10:00 am (EDT) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs.
- Incyte to Present at Upcoming Investor ConferenceIncyte (NASDAQ:INCY) announced today that it will present at the Goldman Sachs Healthcare Conference on Monday, June 9, 2025 at 11:20 am (ET). The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington
- Incyte to Present at Upcoming Investor ConferenceIncyte (NASDAQ:INCY) announced today that it will present at the 2025 BofA Securities Health Care Conference on Tuesday, May 13, 2025 at 1:40 pm (PDT). The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in
- Incyte to Present at Upcoming Investor ConferencesIncyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of March: Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 11:10 am (EST) Leerink Partners 2025 Global Healthcare Conference on Tuesday, March 11, 2025 at 9:20 am (EST) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has
- Incyte to Present at Upcoming Investor ConferenceIncyte (NASDAQ:INCY) announced today that it will present at the 43rd Annual J. P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 am (PST). The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headqua
- Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular LymphomaThe pivotal Phase 3 inMIND trial met its primary endpoint of progression-free survival (PFS) and key secondary endpoints in patients with relapsed or refractory follicular lymphoma (FL) treated with tafasitamab (Monjuvi®) in combination with lenalidomide and rituximab Positive data featured in a late-breaking oral presentation at the 2024 American Society of Hematology (ASH) Annual Meeting support the planned U.S. filing of a supplemental Biologics License Application (sBLA) for tafasitamab in FL by year-end 2024 Incyte to host virtual analyst and investor event on Thursday, December 12, 2024, from 4:00-5:00 p.m. ET to discuss key data presented at ASH Incyte (NASDAQ:INCY) today a
- Incyte Announces Updated Presentation Time for Upcoming Investor ConferenceIncyte (NASDAQ:INCY) announced today that it will now present at Citi's 2024 Global Healthcare Conference on Tuesday, December 3, 2024 at 8:00 a.m. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in W
- Incyte to Present at Upcoming Investor ConferenceIncyte (NASDAQ:INCY) announced today that it will present at Citi's 2024 Global Healthcare Conference on Tuesday, December 3, 2024 at 3:15 p.m. in Miami. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered i
- Incyte to Present at Upcoming Investor ConferencesIncyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of November: Guggenheim's Inaugural Healthcare Innovation Conference on Monday, November 11, 2024 at 2:00 pm (EST) Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 9:30 am (GMT) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyt
- Incyte's Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium- Phase 3 POD1UM-303/InterAACT2 trial met primary endpoint of progression-free survival and demonstrated improvement across secondary endpoints in patients with squamous cell anal carcinoma (SCAC) taking retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) - Late-breaking data presented at the European Society for Medical Oncology (ESMO) Congress 2024 support the planned U.S. filing of a supplemental Biologics License Application (sBLA) for retifanlimab in SCAC by year-end 2024 - Incyte to host an in-person analyst and investor event to review key data at ESMO on Saturday, September 14, 2024 from 1:00-2:30 p.m. ET (7:00-8:30 p.m. CEST) Incyte (NASDAQ:INCY
- Incyte to Present at Upcoming Investor ConferencesIncyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of September: Wells Fargo Healthcare Conference on Wednesday, September 4, 2024 at 12:45 pm (EDT) Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6, 2024 at 10:45 am (EDT) Cantor Global Healthcare Conference on Thursday, September 19, 2024 at 9:45 am (EDT) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical ne
- Incyte to Present at Upcoming Investor ConferenceIncyte (NASDAQ:INCY) announced today that it will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 8:00 a.m. (EDT) in Miami. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoim
- Incyte to Present at Upcoming Investor ConferenceIncyte (NASDAQ:INCY) announced today that it will present at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 at 8:00 a.m. (PDT) in Las Vegas. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Au
- Incyte to Present at Upcoming Investor ConferenceIncyte (NASDAQ:INCY) announced today that it will present at the Cowen 44th Annual Health Care Conference on Monday, March 4, 2024 at 9:50 a.m. (EST) in Boston. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headq
- Incyte to Present at Upcoming Investor ConferencesIncyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of January: Goldman Sachs Annual Healthcare CEOs Unscripted Conference: A View from the Top on Thursday, January 4, 2024 at 9:30 am (EST) 42nd Annual J. P. Morgan Healthcare Conference on Monday, January 8, 2024 at 7:30 am (PST) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therap
- Incyte to Present at Upcoming Investor ConferencesIncyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of November: Guggenheim Securities 5th Annual Inflammation, Neurology & Immunology (INI) Conference on Tuesday, November 7, 2023 at 1:10 pm (EST) Evercore ISI 6th Annual HealthCONx Conference on Thursday, November 30, 2023 at 12:30 pm (EST) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of
- Incyte to Present at Upcoming Investor ConferencesIncyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of September: Wells Fargo 2023 Healthcare Conference on Thursday, September 7, 2023 at 8:45 am (EDT) Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023 at 11:20 am (EDT) Bank of America 2023 Global Healthcare Conference on Thursday, September 14, 2023 at 8:15 am (BST) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medic
- Incyte to Present at Upcoming Investor ConferencesIncyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of June: William Blair 43rd Annual Growth Stock Conference on Tuesday, June 6, 2023 at 11:20 a.m. (CDT) Goldman Sachs 44th Annual Global Healthcare Conference on Monday, June 12, 2023 at 8:40 a.m. (PDT) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For addit
- Incyte to Present at Upcoming Investor ConferencesIncyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of May: Bank of America 2023 Health Care Conference on Wednesday, May 10, 2023 at 10:40 a.m. (PDT) 2023 RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023 at 10:30 a.m. (EDT) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional i
- Incyte to Present at Upcoming Investor ConferenceIncyte (NASDAQ:INCY) announced today that it will present at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 11:10 a.m. (EST) in Boston. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte. View source version on businesswire.com: https://www.businesswire.com/news/home/202302160050
- Incyte to Present at Upcoming Investor ConferenceIncyte (NASDAQ:INCY) announced today that it will present at the Guggenheim Healthcare Talks l Oncology Day on Wednesday, February 8, 2023 at 1:35 p.m. (EST) in New York. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte. View source version on businesswire.com: https://www.businesswire.com/news/home/202
- Incyte to Present at Upcoming Investor ConferencesIncyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of January: Goldman Sachs Annual Healthcare CEOs Unscripted Conference: A View from the Top on Thursday, January 5, 2023 at 9:45 am (EST) 41st Annual J. P. Morgan Healthcare Conference on Monday, January 9, 2023 at 7:30 am (PST) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics
- Incyte to Present at Upcoming Investor ConferencesIncyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of November and December: Evercore ISI 5th Annual HealthCONx Conference (Virtual) on Tuesday, November 29, 2022 at 12:35 pm (EST) Bank of America Securities 2022 Biotech SMID Cap Conference on Wednesday, December 7, 2022 at 8:35 am (EST) in Boston The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization
- Incyte to Present at Upcoming Investor ConferenceIncyte (NASDAQ:INCY) announced today that it will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022 at 12:30 p.m. (EDT) in New York. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte. View source version on businesswire.com: https://www.businesswire.com/n
- Incyte to Present at Upcoming Investor ConferenceIncyte (NASDAQ:INCY) announced today that it will present at the 43rd Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 14, 2022 at 8:00 a.m. (PDT) /11 a.m. (EDT) in Rancho Palos Verdes. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte. View source version on businesswire.com: https://w
- Incyte to Present at Upcoming Investor ConferenceIncyte (NASDAQ:INCY) announced today that it will present at the 2022 RBC Capital Markets Healthcare Conference on Tuesday, May 17, 2022 at 10:30 a.m. ET in New York. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte. View source version on businesswire.com: https://www.businesswire.com/news/home/20220504
- Incyte to Present at Upcoming Investor ConferenceIncyte (NASDAQ:INCY) announced today that it will present at the virtual Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022 at 9:50 a.m. ET. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte. View source version on businesswire.com: https://www.businesswire.com/news/home/20220215005154/en/
- Incyte to Present at Upcoming Investor ConferenceIncyte (NASDAQ:INCY) announced today that it will present at the 11th Annual SVB Leerink Global Healthcare Conference (Virtual) on Thursday, February 17, 2022 at 11:20 a.m. ET. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte. View source version on businesswire.com: https://www.businesswire.com/news/ho
- Incyte to Present at Upcoming Investor ConferencesIncyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of January: Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference: A View from the Top (Virtual) on Thursday, January 6, 2022 at 3:00 pm (EST) 40th Annual J. P. Morgan Healthcare Conference on Monday, January 10, 2022 at 7:30 am (PST) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprie
- Incyte to Present at Upcoming Investor ConferenceIncyte (NASDAQ:INCY) announced today that it will present at the Evercore ISI 4th Annual HealthCONx Conference (Virtual) on Tuesday, November 30, 2021 at 2:15 p.m. ET. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte. View source version on businesswire.com: https://www.businesswire.com/news/home/2021110
- Incyte Announces Ruxolitinib Cream Data Accepted for Presentation at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual CongressData from the Phase 3 TRuE-V program of ruxolitinib cream in vitiligo to be presented for the first time in a late-breaking oral presentation Incyte (NASDAQ:INCY) today announced that multiple abstracts highlighting data for ruxolitinib cream, an investigational topical JAK1/JAK2 inhibitor, in patients with vitiligo and atopic dermatitis (AD) will be presented at the upcoming European Academy of Dermatology and Venereology (EADV) 30th Anniversary Congress, held virtually from September 29-October 2, 2021. The 24-week data from the Phase 3 TRuE-V program evaluating the safety and efficacy of ruxolitinib cream in adolescent and adult patients (age ≥12 years) with vitiligo will be presente
- Incyte to Present at Upcoming Investor ConferenceIncyte (NASDAQ:INCY) announced today that it will present at the Morgan Stanley 19th Annual Global Healthcare Conference (Virtual) on Monday, September 13, 2021 at 11:45 a.m. ET. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 90 days. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte. View source version on businesswire.com: https://www.businesswire.com/news/h
- Incyte Announces Updated Data for Ruxolitinib Cream Accepted for Presentation at the 2021 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference-- First presentation of long-term safety and disease control data from Phase 3 TRuE-AD studies of ruxolitinib cream in atopic dermatitis Incyte (NASDAQ:INCY) today announced that multiple abstracts highlighting updated data for ruxolitinib cream, an investigational topical JAK1/JAK2 inhibitor, in patients with atopic dermatitis (AD) will be presented at the upcoming 2021 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference, held on June 13, 2021. "Atopic dermatitis, the most common type of eczema, can be difficult to manage and can have a significant impact on patients' lives," said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & AutoImmunity, Incyte. "We are pleased to
- Incyte to Present at Upcoming Investor ConferencesIncyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of June: William Blair 41st Annual Growth Stock Conference (Virtual) on Thursday, June 3, 2021 at 1:00 pm (EDT) BioPharma Sustainability Roundtable's CEO Investor Forum on Monday, June 7, 2021 at 1:35 pm (EDT) Goldman Sachs 42nd Annual Global Healthcare Conference (Virtual) on Tuesday, June 8, 2021 at 8:00 am (EDT) Guggenheim's "Biopharma's Next Decade: Views from the Top on Global Strategy and Innovation" Series on Monday, June 28, 2021 at 11:00 am (EDT) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay.
- Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical ProgramsTotal product and royalty revenues of $605 million in Q1 2021 (+6% vs Q1 2020) Jakafi® (ruxolitinib) revenues of $466 million in Q1 2021 (+1% vs Q1 2020); reaffirming full year guidance of $2.125-$2.20 billion Pemazyre® (pemigatinib) now also approved in Europe and Japan, becoming the first internally discovered product to be globally commercialized by Incyte Three regulatory submissions accepted by the FDA for Priority Review, including potential approval of ruxolitinib cream in the U.S. for atopic dermatitis in June Conference Call and Webcast Scheduled Today at 8:00 a.m. EDT Incyte (NASDAQ:INCY) today reports 2021 first quarter financial results, and provides a status update
- Incyte to Present at Upcoming Investor ConferenceIncyte (NASDAQ:INCY) announced today that it will present at the Bank of America Securities Virtual 2021 Healthcare Conference on Thursday, May 13, 2021 at 12:30 p.m. ET. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 90 days. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte. View source version on businesswire.com: https://www.businesswire.com/news/home/202
- Incyte to Present at Upcoming Investor ConferenceWILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the virtual Cowen 41st Annual Health Care Conference on Wednesday, March 3, 2021 at 2:00 p.m. EST. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 90 days. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
- Incyte to Present at Upcoming Investor ConferenceWILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the 39th Annual J. P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021 at 7:30 a.m. EST. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 90 days. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
- Incyte Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin LymphomasWILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced data from three ongoing Phase 2 studies evaluating parsaclisib, a potent, highly selective, next-generation oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ), for the treatment of patients with relapsed or refractory follicular (CITADEL-203), marginal zone (CITADEL-204) and mantle cell (CITADEL-205) lymphomas. These data were accepted for presentation at the 62nd American Society of Hematology Annual Meeting and Exposition (ASH 2020), held virtually from December 5–8, 2020. The primary endpoint for the CITADEL-203, -204 and -205 studies is objective response rate (ORR); duration of response (DOR), p
- Incyte Announces First Data from REACH3 Trial Showing Ruxolitinib (Jakafi®) Significantly Improved Outcomes in Patients with Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host DiseaseWILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that detailed results from the pivotal Phase 3 REACH3 study demonstrate Jakafi® (ruxolitinib) significantly improved outcomes across a range of efficacy measures in patients with steroid-refractory or steroid-dependent chronic graft-versus-host disease (GVHD) compared to best available therapy (BAT)1. The results of REACH3, the first successful, randomized Phase 3 trial in chronic GVHD, were highlighted in a press briefing today and will be presented during the 62nd American Society of Hematology Annual Meeting & Exposition (ASH 2020). REACH3 is jointly sponsored by Incyte and Novartis. “The results from this